Transarterial Chemoembolization (TACE) Market is Growing at a Promising CAGR of 8.57% During Forecast 2019-2025
Market Forecast: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs mainly due to chronic liver disease and cirrhosis. It is the third leading cause of cancer deaths worldwide, with over 500,000 people affected. Transarterial chemoembolization is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC. The global Transarterial Chemoembolization (TACE) Market Is expected to exhibit a CAGR of 8.57% to reach USD 2777.22 billion by 2025 . Market Influencer: Improvement in the reimbursement scenario and increasing incidence of HCC are impacting the growth of the market. HCC accounts for approximately 70% to 90% of all primary liver cancers and is the third most fatal cancer worldwide. Moreover, Lipiodol is approved for National Health Insurance reimbursement for transcatheter arterial chemoembolization for HCC. Key Players : · ...